TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Faruqi & Faruqi, Llp
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Tvardi Therapeutics experienced an 80% stock drop after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.

Insights
GOOG   neutral

Mentioned as providing warrant pledges, with no direct negative or positive implications


TVRD   negative

Stock plummeted over 80% due to unsuccessful clinical trial results, indicating poor performance and potential investor losses